HOME > COMMENTARY
COMMENTARY
-
SGLT-2 Inhibitor Sales Would Plunge If Used Only in Younger, Obese Patients, but Cautious Administration Warranted
March 17, 2015
-
Uncertainty Swirling around Possible Drug Price Cuts for 3 Straight Years
March 16, 2015
-
Drug Repositioning May Promise Greater Chance of Success, but Problems Remain
March 6, 2015
-
As Adjuvant Development Race Heats Up, New Databases Could Turn Japan into Global Vaccine Powerhouse
February 16, 2015
-
Japan Poised to Tap Its Version of “Compassionate Use” to Combat Challenges Left for Unapproved Drugs
February 2, 2015
-
Open Innovation Bandwagon Gathers Pace for Efficient Drug Discovery
January 26, 2015
-
Have AGs Finally Become a Good Option to Counter Generics?
January 19, 2015
-
Will Legal Regulation Propel or Stymie Clinical Research? “Risk-Based” Approach Holds Key
January 13, 2015
-
Can Pharmas and Wholesalers Work to Dispel “Negative Primary Margins on Sales”?
December 22, 2014
-
April-Sept. Earnings Signal Watershed in Japan’s Shift to Generics
December 15, 2014
-
Wonder Drug? Savior? Avigan Clinical Trial for Ebola May Not Provide Clear-Cut Answer
December 5, 2014
-
Torii Eager to Carve Out New Market with Japan’s 1st Sublingual Allergen Immunotherapy
November 25, 2014
-
Was Weak Yen a Plus for April-Sept. Earnings? Profits Partly Canceled Out by Higher R&D, Import Costs
November 18, 2014
-
JPWA’s Uniform Tax Representation Will Benefit Wholesalers and Customers Alike
November 10, 2014
-
Can a More-Open ICH Maintain “Tri-Polar” Leadership? - Key Focus at Lisbon Meeting
November 5, 2014
-
Ex-Health Minister Tamura’s Clout Likely to Grow in Nagatacho
October 14, 2014
-
MHLW Has Trick Up Its Sleeve to Skirt 3 Straight Years of “Full-Scale” NHI Price Revisions
October 6, 2014
-
Revised PAL to Embrace “Deeper” Safety Measures, Yet Also Escape Clauses to Ease Company Burdens
September 29, 2014
-
Series of CRPC Drugs Make Japan Debut, Expanded Indications Key to Success
September 24, 2014
-
Picture of Future Regulations on Investigator-Led Clinical Research Emerging
September 9, 2014
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…